The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Being started on a smaller dose of the approved early Alzheimer’s therapy Kisunla was found to reduce the risk of ARIA-E on imaging scans.

Approved for use on the NHS last year and manufactured by pharmaceutical firm Eli Lilly, tirzepatide - also known under brand ...

Past comments by Robert F. Kennedy Jr. hint at the ideas he might advocate for if given a role in the incoming Trump ...

NICE has said it expects to evaluate dozens of potential treatments for Alzheimer’s disease over the next few years. Elisabeth Mahase examines what we know about these drugs This year the National ...

Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...

Use of the weight loss drug was also linked to shorter hospital stays. Eli Lilly and Novo Nordisk are the main players in the GLP-1 field, but they're facing competition from compounding pharmacies, ...

NOW 21% 79.12% 78.32% 19.20% 15.30% BlackRock Inc. BLK 21% 81.09% 76.52% 41.79% 40.61% MarketAxess Holdings Inc. MKTX 20% 79.96% 78.86% 54.22% 47.86% Eli Lilly & Co. LLY 20% 81.02% 80.42% 42.85% 40.39 ...

But what makes Altimmune's drug different from existing drugs, and what kind of market opportunity does it have? Altimmune's ...

Even a juggernaut like Eli Lilly ( LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...